

Warning and Precautions

Read the label before opening the container. Wear protective gloves/protective clothing/eye protection/ face protection. Follow good microbiological lab practices while handling specimens and culture. Standard precautions as per established guidelines should be followed while handling specimens. Safety guidelines may be referred in individual safety data sheets.

Quality Control

Appearance

Cream to yellow homogeneous free flowing powder

Gelling

Firm, comparable with 2.5% Agar gel.

Colour and Clarity of prepared medium

Amber coloured clear to slightly opalescent gel forms in Petri plates

Reaction

Reaction of 8.5% w/v aqueous solution at 25°C. pH : 6.6±0.2

pH

6.40-6.80

Cultural Response

Average diameter of zone of inhibition observed after an incubation at 25-30°C for 48-72 hours.

Organism	Growth	Zone of inhibition (Amphotericin B 50mcg)	Zone of inhibition (Nystatin 50mcg)	Zone of inhibition (Miconazole 50mcg)	Zone of inhibition (Miconazole 30mcg)	Zone of inhibition (Ketoconazole 50mcg)
<i>Candida albicans</i> ATCC 90028	Luxuriant	12 - 15mm	19 - 23mm	26 - 32mm	22-26mm	30 - 37mm
<i>Candida parapsilosis</i> ATCC 22019	11-18mm	13 - 17mm	19 - 23mm	23 - 29mm	13 - 17mm	27 - 33mm

Reference

- 1.Rex, J.H. et al 1997 for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24 : 235-247
- 2.National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; Approved standard M27-A.
- 3.Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guidelines-Second edition Vol.29 No.17, August- 2009 CLSI document M44-A2. For more details refer to this volume
- 4.Zone Diameter Interpretive Standards, Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints, and Quality Control Limits for Antifungal Disk Diffusion Susceptibility Testing Of Yeasts, Third International Supplement CLSI document - M44-S3.
National Committee for Clinical Laboratory Standards, villanova, Pa.
- 5.Espinel –Ingroff et al (1992) J.Clin. Microbiol . 30: 3138-3145
- 6.Stiller R.L. et al (1983) J.Infec. Dis 147: 1070-1076
- 7.Pfaller M.A et al (1988) J.Clin.Microbiol 26: 1437-1441
- 8.Barry A.L. and S.D. Brown. 1996. J. Clin. Microbiol.34:2154-2157

Revision : 1 / 2011

Disclaimer :

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMedia™ publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMedia™ Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory,diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.
